PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1454092
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1454092
Coronavirus Vaccine Market Forecasts to 2030 - Global Analysis By Vaccine Type, Age Group, Route of Administration, Distribution Channel, Technology and By Geography
According to Stratistics MRC, the Global Coronavirus Vaccine Market is accounted for $43.9 billion in 2023 and is expected to reach $82.3 billion by 2030 growing at a CAGR of 9.4% during the forecast period. A Coronavirus Vaccine is a medical substance developed to provide immunity against the novel coronavirus, SARS-CoV-2, which causes COVID-19. It stimulates the body's immune system to recognize and neutralize the virus, preventing infection or reducing the severity of symptoms if exposure occurs. Most vaccines target the virus's spike protein, which it uses to enter human cells. Different types of vaccines, including mRNA, viral vector, protein subunit, and inactivated virus vaccines, have been developed and authorized for emergency use globally.
According to the National Institutes of Health (NIH), the Pfizer-BioNTech COVID-19 vaccine received FDA approval for commercialization on 23 August 2021.
Market Dynamics:
Driver:
Urgent global need
The COVID-19 pandemic had unprecedented global impact, causing widespread illness, death, economic disruption, and social upheaval. Vaccines are recognized as a critical tool in controlling the spread of the virus, reducing the burden on healthcare systems, and ultimately saving lives. Moreover, governments, healthcare organizations, and the public are acutely aware of the urgency to develop, produce, and distribute vaccines on a massive scale. The urgency is further heightened by the emergence of new variants of the virus, emphasizing the need for continued vigilance and adaptation in vaccine development, which has accelerated market demand.
Restraint:
Manufacturing constraints
The rapid global demand for COVID-19 vaccines has strained manufacturing capacities, leading to supply shortages, delays in production, and distribution challenges. Several factors contribute to these constraints, including the complexity of vaccine production processes, limited manufacturing facilities equipped for vaccine production, and shortages of raw materials and specialized equipment. Additionally, shortages of critical components, such as lipid nanoparticles used in mRNA vaccine formulations, can disrupt manufacturing timelines and limit production capacity. As a result, manufacturing constraints are a significant factor hampering market demand.
Opportunity:
Government support
With the COVID-19 pandemic posing unprecedented public health challenges, governments worldwide have mobilized substantial resources, funding, and regulatory support to accelerate vaccine development, production, and distribution efforts. Additionally, governments have provided financial investments, research grants, and incentives to pharmaceutical companies and research institutions to expedite vaccine development timelines and scale up manufacturing capacity. Therefore, government support is a factor propelling market demand.
Threat:
Vaccine efficacy and safety concerns
Vaccine efficacy and safety concerns represent a significant restraint in the coronavirus vaccine market. Concerns regarding vaccine efficacy relate to how well a vaccine prevents infection or reduces the severity of the disease. Additionally, safety concerns regarding vaccines encompass potential adverse reactions, side effects, or long-term health implications. Reports of rare but serious adverse events following vaccination, such as blood clotting disorders or myocarditis, have raised concerns, eroded public confidence in vaccine safety, and impacted market growth.
Covid-19 Impact
The impact of COVID-19 on the coronavirus vaccine market has been profound and multifaceted. COVID-19 spurred unprecedented collaboration among scientists, researchers, pharmaceutical companies, and governments to accelerate vaccine development timelines. Moreover, the pandemic necessitated the rapid deployment of innovative vaccine technologies, such as mRNA and viral vector platforms, leading to the development and approval of multiple COVID-19 vaccines in record time.
The RNA vaccine segment is expected to be the largest during the forecast period
The RNA vaccine segment is estimated to hold the largest share. These vaccines utilize a novel technology based on messenger RNA (mRNA) to instruct cells in the body to produce a viral protein, triggering an immune response against the virus. The development of RNA vaccines offers several advantages, including rapid production and scalability. Additionally, RNA vaccines can be easily modified to target new variants of the virus by updating the mRNA sequence to match emerging strains, enhancing their versatility and adaptability in combating the evolving nature of the pandemic.
The recombinant vaccines segment is expected to have the highest CAGR during the forecast period
The recombinant vaccines segment is anticipated to have lucrative growth during the forecast period. These vaccines are developed using recombinant DNA technology, where specific genes from the SARS-CoV-2 virus, such as those encoding the spike protein, are inserted into host cells, such as yeast or mammalian cells, to produce viral proteins. Recombinant vaccines do not contain live virus particles, eliminating the risk of causing disease. This makes them suitable for individuals with compromised immune systems or other health conditions. Furthermore, recombinant vaccine production is highly scalable and can be rapidly scaled up to meet global demand.
Region with largest share:
North America commanded the largest market share during the extrapolated period. North America has been at the forefront of vaccine innovation, with several leading pharmaceutical companies headquartered in the region spearheading the development of COVID-19 vaccines. These companies have leveraged cutting-edge technologies, such as mRNA and recombinant DNA, to rapidly develop vaccines with high efficacy and safety profiles. Furthermore, governments in North America have provided substantial financial investments, regulatory support, and procurement initiatives to expedite vaccine development and ensure widespread access to vaccines for their populations.
Region with highest CAGR:
Asia Pacific is expected to witness profitable growth over the projection period, due to its large population, diverse healthcare landscape, and emerging economies. China and India, in particular, have emerged as key players in vaccine manufacturing, producing large quantities of COVID-19 vaccines for domestic use and global distribution. These countries have leveraged their manufacturing capabilities and extensive vaccine production infrastructure to supply vaccines to both domestic and international markets. Moreover, several countries in the Asia-Pacific region have actively participated in vaccine research and development, contributing to the global effort to combat the pandemic.
Key players in the market
Some of the key players in the Coronavirus Vaccine Market include Moderna, AstraZeneca, Sinopharm, Pfizer-BioNTech, Sinovac, Johnson & Johnson, Serum Institute of India, Bharat Biotech, Gamaleya Research Institute, Novavax, CureVac, CanSino Biologics, Sanofi-GSK, GlaxoSmithKline and Entos Pharmaceuticals.
Key Developments:
In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.
In July 2023, AstraZeneca, a global biopharmaceutical company, announced collaboration with Absci Corporation. This collaboration combines Absci's Integrated Drug Creation(TM) platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.
In January 2022, Pfizer Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles a debilitating, disfiguring and painful disease that impacts about one in three people in the United States during their lifetime.
In April 2020, Johnson & Johnson announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate.
Vaccine Types Covered:
- Repurposed Vaccines
- Inactivated Virus
- Non-replicating Viral Vector
- Protein Subunit
- DNA Vaccine
- RNA Vaccine
Age Groups Covered:
- 12 to 18
- Above 18
Route of Administrations Covered:
- Intradermal
- Intramuscular
- Intranasal
- Other Route of Administrations
Distribution Channels Covered:
- Hospitals and Clinics
- Government Entities
- Vaccination Centers
- Other Distribution Channels
Technologies Covered:
- Synthetic Vaccines
- Recombinant Vaccines
- Live Attenuated Vaccines
- Conventional Vaccines
- Other Technologies
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Coronavirus Vaccine Market, By Vaccine Type
- 5.1 Introduction
- 5.2 Repurposed Vaccines
- 5.3 Inactivated Virus
- 5.4 Non-replicating Viral Vector
- 5.5 Protein Subunit
- 5.6 DNA Vaccine
- 5.7 RNA Vaccine
6 Global Coronavirus Vaccine Market, By Age Group
- 6.1 Introduction
- 6.2 12 to 18
- 6.3 Above 18
7 Global Coronavirus Vaccine Market, By Route of Administration
- 7.1 Introduction
- 7.2 Synthetic Vaccines
- 7.3 Intradermal
- 7.4 Intramuscular
- 7.5 Intranasal
- 7.6 Other Route of Administrations
8 Global Coronavirus Vaccine Market, By Distribution Channel
- 8.1 Introduction
- 8.2 Hospitals and Clinics
- 8.3 Government Entities
- 8.4 Vaccination Centers
- 8.5 Other Distribution Channels
9 Global Coronavirus Vaccine Market, By Technology
- 9.1 Introduction
- 9.2 Synthetic Vaccines
- 9.3 Recombinant Vaccines
- 9.4 Live Attenuated Vaccines
- 9.5 Conventional Vaccines
- 9.6 Other Technologies
10 Global Coronavirus Vaccine Market, By Geography
- 10.1 Introduction
- 10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
- 10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
- 10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa
11 Key Developments
- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies
12 Company Profiling
- 12.1 Moderna
- 12.2 AstraZeneca
- 12.3 Sinopharm
- 12.4 Pfizer-BioNTech
- 12.5 Sinovac
- 12.6 Johnson & Johnson
- 12.7 Serum Institute of India
- 12.8 Bharat Biotech
- 12.9 Gamaleya Research Institute
- 12.10 Novavax
- 12.11 CureVac
- 12.12 CanSino Biologics
- 12.13 Sanofi-GSK
- 12.14 GlaxoSmithKline
- 12.15 Entos Pharmaceuticals
List of Tables
- Table 1 Global Coronavirus Vaccine Market Outlook, By Region (2021-2030) ($MN)
- Table 2 Global Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
- Table 3 Global Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
- Table 4 Global Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
- Table 5 Global Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
- Table 6 Global Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
- Table 7 Global Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
- Table 8 Global Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
- Table 9 Global Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
- Table 10 Global Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
- Table 11 Global Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
- Table 12 Global Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 13 Global Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
- Table 14 Global Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
- Table 15 Global Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
- Table 16 Global Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 17 Global Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 18 Global Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
- Table 19 Global Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
- Table 20 Global Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
- Table 21 Global Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 22 Global Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
- Table 23 Global Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
- Table 24 Global Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 25 Global Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
- Table 26 Global Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
- Table 27 Global Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 28 North America Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
- Table 29 North America Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
- Table 30 North America Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
- Table 31 North America Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
- Table 32 North America Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
- Table 33 North America Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
- Table 34 North America Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
- Table 35 North America Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
- Table 36 North America Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
- Table 37 North America Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
- Table 38 North America Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
- Table 39 North America Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 40 North America Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
- Table 41 North America Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
- Table 42 North America Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
- Table 43 North America Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 44 North America Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 45 North America Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
- Table 46 North America Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
- Table 47 North America Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
- Table 48 North America Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 49 North America Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
- Table 50 North America Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
- Table 51 North America Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 52 North America Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
- Table 53 North America Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
- Table 54 North America Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 55 Europe Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
- Table 56 Europe Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
- Table 57 Europe Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
- Table 58 Europe Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
- Table 59 Europe Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
- Table 60 Europe Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
- Table 61 Europe Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
- Table 62 Europe Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
- Table 63 Europe Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
- Table 64 Europe Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
- Table 65 Europe Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
- Table 66 Europe Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 67 Europe Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
- Table 68 Europe Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
- Table 69 Europe Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
- Table 70 Europe Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 71 Europe Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 72 Europe Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
- Table 73 Europe Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
- Table 74 Europe Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
- Table 75 Europe Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 76 Europe Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
- Table 77 Europe Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
- Table 78 Europe Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 79 Europe Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
- Table 80 Europe Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
- Table 81 Europe Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 82 Asia Pacific Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
- Table 83 Asia Pacific Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
- Table 84 Asia Pacific Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
- Table 85 Asia Pacific Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
- Table 86 Asia Pacific Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
- Table 87 Asia Pacific Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
- Table 88 Asia Pacific Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
- Table 89 Asia Pacific Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
- Table 90 Asia Pacific Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
- Table 91 Asia Pacific Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
- Table 92 Asia Pacific Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
- Table 93 Asia Pacific Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 94 Asia Pacific Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
- Table 95 Asia Pacific Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
- Table 96 Asia Pacific Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
- Table 97 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 98 Asia Pacific Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 99 Asia Pacific Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
- Table 100 Asia Pacific Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
- Table 101 Asia Pacific Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
- Table 102 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 103 Asia Pacific Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
- Table 104 Asia Pacific Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
- Table 105 Asia Pacific Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 106 Asia Pacific Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
- Table 107 Asia Pacific Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
- Table 108 Asia Pacific Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 109 South America Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
- Table 110 South America Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
- Table 111 South America Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
- Table 112 South America Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
- Table 113 South America Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
- Table 114 South America Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
- Table 115 South America Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
- Table 116 South America Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
- Table 117 South America Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
- Table 118 South America Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
- Table 119 South America Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
- Table 120 South America Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 121 South America Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
- Table 122 South America Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
- Table 123 South America Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
- Table 124 South America Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 125 South America Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 126 South America Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
- Table 127 South America Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
- Table 128 South America Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
- Table 129 South America Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 130 South America Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
- Table 131 South America Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
- Table 132 South America Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 133 South America Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
- Table 134 South America Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
- Table 135 South America Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
- Table 136 Middle East & Africa Coronavirus Vaccine Market Outlook, By Country (2021-2030) ($MN)
- Table 137 Middle East & Africa Coronavirus Vaccine Market Outlook, By Vaccine Type (2021-2030) ($MN)
- Table 138 Middle East & Africa Coronavirus Vaccine Market Outlook, By Repurposed Vaccines (2021-2030) ($MN)
- Table 139 Middle East & Africa Coronavirus Vaccine Market Outlook, By Inactivated Virus (2021-2030) ($MN)
- Table 140 Middle East & Africa Coronavirus Vaccine Market Outlook, By Non-replicating Viral Vector (2021-2030) ($MN)
- Table 141 Middle East & Africa Coronavirus Vaccine Market Outlook, By Protein Subunit (2021-2030) ($MN)
- Table 142 Middle East & Africa Coronavirus Vaccine Market Outlook, By DNA Vaccine (2021-2030) ($MN)
- Table 143 Middle East & Africa Coronavirus Vaccine Market Outlook, By RNA Vaccine (2021-2030) ($MN)
- Table 144 Middle East & Africa Coronavirus Vaccine Market Outlook, By Age Group (2021-2030) ($MN)
- Table 145 Middle East & Africa Coronavirus Vaccine Market Outlook, By 12 to 18 (2021-2030) ($MN)
- Table 146 Middle East & Africa Coronavirus Vaccine Market Outlook, By Above 18 (2021-2030) ($MN)
- Table 147 Middle East & Africa Coronavirus Vaccine Market Outlook, By Route of Administration (2021-2030) ($MN)
- Table 148 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intradermal (2021-2030) ($MN)
- Table 149 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intramuscular (2021-2030) ($MN)
- Table 150 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intranasal (2021-2030) ($MN)
- Table 151 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
- Table 152 Middle East & Africa Coronavirus Vaccine Market Outlook, By Distribution Channel (2021-2030) ($MN)
- Table 153 Middle East & Africa Coronavirus Vaccine Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
- Table 154 Middle East & Africa Coronavirus Vaccine Market Outlook, By Government Entities (2021-2030) ($MN)
- Table 155 Middle East & Africa Coronavirus Vaccine Market Outlook, By Vaccination Centers (2021-2030) ($MN)
- Table 156 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
- Table 157 Middle East & Africa Coronavirus Vaccine Market Outlook, By Technology (2021-2030) ($MN)
- Table 158 Middle East & Africa Coronavirus Vaccine Market Outlook, By Synthetic Vaccines (2021-2030) ($MN)
- Table 159 Middle East & Africa Coronavirus Vaccine Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
- Table 160 Middle East & Africa Coronavirus Vaccine Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
- Table 161 Middle East & Africa Coronavirus Vaccine Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
- Table 162 Middle East & Africa Coronavirus Vaccine Market Outlook, By Other Technologies (2021-2030) ($MN)
